Open-Label Trial of Nilotinib in Patients With Advanced (>CP1) Chronic Myeloid Leukemia or Ph+ Acute Lymphatic Leukemia Pre- and Post- Allogeneic Stem Cell Transplantation.

Trial Profile

Open-Label Trial of Nilotinib in Patients With Advanced (>CP1) Chronic Myeloid Leukemia or Ph+ Acute Lymphatic Leukemia Pre- and Post- Allogeneic Stem Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Dec 2015 Planned End Date changed from 1 Jul 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 02 Dec 2015 Planned primary completion date changed from 1 Jul 2014 to 1 May 2016 as reported by ClinicalTrials.gov
    • 24 Nov 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top